Alnylam Pharmaceuticals

A Busy Month in the Business of microRNA

by Chris on June 30, 2010

in Press Release

BUSINESSWIRE -

June 29th – Alnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR)

June 29th – Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer

June 28th – Reimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel Through World’s Second Largest HMO

June 28th – Alnylam Scientists and Collaborators Publish Research in Nature Chemical Biology on a Novel Mechanism for Regulation of Gene Expression with Anti-Gene RNAs (agRNAs)

June 23rd – Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliance to Develop microRNA-Targeted Medicines for the Treatment of Cardiovascular Disease

June 23rd – Alnylam Biotherapeutics Presents New Data on RNAi Applications in Biotherapeutics Manufacturing

June 22nd – Isis and Alnylam Provide Update on Regulus’ Strategic Alliance with Sanofi-Aventis

June 22nd – Sanofi-Aventis and Regulus Therapeutics Form Major Strategic Alliance on microRNA Therapeutics

June 21st – Mirna Therapeutics Recommended for $10 Million Commercialization Award from the Cancer Prevention and Research Institute of Texas

June 17th – Alnylam Secures Intellectual Property and Technology for RNAi Applications in Vaccine Research and Development

June 17th – Alnylam Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Broadly Covering RNAi Therapeutics that Target Mutated Genes

June 7th – Data Presented at ASCO 2010 by M. D. Anderson Researchers Demonstrate the ability of miRview™ mets to Identify the Most Likely Origin of Metastases in Cancer of Unknown Primary

June 3rd – Rosetta Genomics Establishes “Rosetta Green” as Majority-owned Subsidiary


{ 1 comment }

Alnylam Pharmaceuticals & Regulus Therapeutics in the News

by Chris on November 12, 2009

in News

11/12/09 – CAMBRIDGE, Mass.–( Business Wire)–Alnylam Pharmaceuticals, Inc. an RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the “Investors” section of the company’s website at www.alnylam.com. Alnylam’s R&D Day will be held on Thursday, November 12, 2009 from 8:30 a.m. to 12:00 p.m. ET

Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel RNAi therapeutics. In addition, Alnylam will host two guest speakers:

  • Professor Allan R. Glanville, Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital, Sydney, will discuss respiratory syncytial virus (RSV) infection in the lung transplant patient population; and,
  • Professor Philip N. Hawkins, National Amyloidosis Centre, Division of Medicine, and University College London Medical School Royal Free Hospital, will discuss transthyretin (TTR)-mediated amyloidosis.

10/28/09 – CARLSBAD, Calif. & CAMBRIDGE, Mass.–(Business Wire)– Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc. , announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the `Esau` patent family (US Application Serial No. 10/909,125). The Esau patent estate, which is owned exclusively by Regulus, represents one of the earliest filings in the microRNA intellectual property landscape, and is fundamental to the discovery, development, and commercialization of microRNA therapeutics.

“Regulus is advancing a new class of innovative medicines based on microRNAs. Indeed, microRNA therapeutics represent a new frontier of pharmaceutical research where an entire pathway of human disease can be targeted,” said Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus Therapeutics. “This Notice of Allowance is the first in the Esau series, and we expect many more patents covering microRNA therapeutics to issue from this important and early patent family.”

{ 0 comments }